BRPI0715714A2 - Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente - Google Patents
Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um pacienteInfo
- Publication number
- BRPI0715714A2 BRPI0715714A2 BRPI0715714-2A2A BRPI0715714A BRPI0715714A2 BR PI0715714 A2 BRPI0715714 A2 BR PI0715714A2 BR PI0715714 A BRPI0715714 A BR PI0715714A BR PI0715714 A2 BRPI0715714 A2 BR PI0715714A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- treatment
- viral infection
- patient
- resistant
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 7
- 231100000283 hepatitis Toxicity 0.000 title 6
- 208000036142 Viral infection Diseases 0.000 title 5
- 230000009385 viral infection Effects 0.000 title 5
- 208000015181 infectious disease Diseases 0.000 title 2
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 title 1
- 206010057212 Hepatitis viral infections Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012544 monitoring process Methods 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84035306P | 2006-08-25 | 2006-08-25 | |
PCT/US2007/076408 WO2008024763A2 (en) | 2006-08-25 | 2007-08-21 | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0715714A2 true BRPI0715714A2 (pt) | 2014-03-11 |
Family
ID=39022157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715714-2A2A BRPI0715714A2 (pt) | 2006-08-25 | 2007-08-21 | Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente |
Country Status (9)
Country | Link |
---|---|
US (2) | US20080182895A1 (pt) |
AR (1) | AR062482A1 (pt) |
AU (1) | AU2007286754A1 (pt) |
BR (1) | BRPI0715714A2 (pt) |
CA (1) | CA2659461A1 (pt) |
CL (1) | CL2007002447A1 (pt) |
PE (1) | PE20081215A1 (pt) |
TW (1) | TW200816990A (pt) |
WO (1) | WO2008024763A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101437964B (zh) * | 2004-10-18 | 2012-06-13 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
EP2101173A1 (en) * | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
FR2933094A1 (fr) * | 2008-06-26 | 2010-01-01 | Univ Joseph Fourier | Mutations dans la proteine ns5b du vhc. |
US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CH707029B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon. |
AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
DE102014219858B4 (de) | 2014-09-30 | 2021-09-23 | Aktiebolaget Skf | Kreuzgelenk |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
GB201704386D0 (en) * | 2017-03-20 | 2017-05-03 | Univ London Queen Mary | Method for identification of sofosbuvir resistant patients |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9913935A (pt) * | 1998-09-25 | 2001-06-19 | Viropharma Inc | Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo |
DE10030139A1 (de) * | 2000-06-20 | 2002-01-10 | Cmi Ag | Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
JP2004529080A (ja) * | 2000-10-25 | 2004-09-24 | アグネッロ,ヴィンセント | Hcv、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法 |
WO2002048165A2 (en) * | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
TW200400963A (en) * | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
TW200400818A (en) * | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
EP1536804A4 (en) * | 2002-06-28 | 2007-10-31 | Idenix Cayman Ltd | 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS |
US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
WO2004041201A2 (en) * | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
HUE033832T2 (en) * | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
US7125853B2 (en) * | 2003-01-07 | 2006-10-24 | Kemin Pharma B.V.B.A. | Bicyclic carbohydrate compounds useful in the treatment of infections caused by Flaviviridae sp., such as hepatitis C and bovine viral diarrhea viruses |
WO2004084796A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
WO2005000308A2 (en) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
AU2004258750A1 (en) * | 2003-07-25 | 2005-02-03 | Centre National De La Recherche Scientifique -Cnrs | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C |
TW200528459A (en) * | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
JP2005202801A (ja) * | 2004-01-16 | 2005-07-28 | Sharp Corp | 表示装置 |
US20060040944A1 (en) * | 2004-06-23 | 2006-02-23 | Gilles Gosselin | 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
US20060035848A1 (en) * | 2004-08-09 | 2006-02-16 | Zymetx, Inc. | Broad-spectrum inhibitor of viruses in the Flaviviridae family |
TWM262874U (en) * | 2004-08-10 | 2005-04-21 | Starlink Electronics Corp | LGA terminal structure with changed circuit |
JP2008514611A (ja) * | 2004-09-23 | 2008-05-08 | ワイス | C型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体 |
NZ567262A (en) * | 2005-09-30 | 2011-12-22 | Scynexis Inc | Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection |
WO2007059421A2 (en) * | 2005-11-10 | 2007-05-24 | Wyeth | Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same |
EP1948137A2 (en) * | 2005-11-10 | 2008-07-30 | Wyeth a Corporation of the State of Delaware | Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-(2-hydroxyethyl)(methylsulfonyl) amino-n-methyl-1-benzofuran-3-carboxamide and method of making same |
TW200808308A (en) * | 2006-02-09 | 2008-02-16 | Schering Corp | Novel HCV inhibitor combinations and methods |
TW200815384A (en) * | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
-
2007
- 2007-08-21 BR BRPI0715714-2A2A patent/BRPI0715714A2/pt not_active Application Discontinuation
- 2007-08-21 CA CA002659461A patent/CA2659461A1/en not_active Abandoned
- 2007-08-21 US US11/842,312 patent/US20080182895A1/en not_active Abandoned
- 2007-08-21 WO PCT/US2007/076408 patent/WO2008024763A2/en active Application Filing
- 2007-08-21 AU AU2007286754A patent/AU2007286754A1/en not_active Abandoned
- 2007-08-22 CL CL200702447A patent/CL2007002447A1/es unknown
- 2007-08-22 PE PE2007001141A patent/PE20081215A1/es not_active Application Discontinuation
- 2007-08-22 AR ARP070103727A patent/AR062482A1/es unknown
- 2007-08-22 TW TW096131070A patent/TW200816990A/zh unknown
-
2009
- 2009-06-29 US US12/493,736 patent/US20100028922A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2007286754A1 (en) | 2008-02-28 |
CA2659461A1 (en) | 2008-02-28 |
US20080182895A1 (en) | 2008-07-31 |
CL2007002447A1 (es) | 2008-03-14 |
US20100028922A1 (en) | 2010-02-04 |
TW200816990A (en) | 2008-04-16 |
PE20081215A1 (es) | 2008-10-22 |
WO2008024763A2 (en) | 2008-02-28 |
AR062482A1 (es) | 2008-11-12 |
WO2008024763A3 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0715714A2 (pt) | Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente | |
JP2016118568A5 (pt) | ||
WO2011106536A3 (en) | Methods of diagnosing infectious disease pathogens and their drug sensitivity | |
WO2010038993A3 (ko) | 심혈관 분석 장치 | |
WO2008040328A3 (de) | Diagnose von infektionen oder entzündungserkrankungen der atemwege und lunge assoziiert mit herzinsuffizienz | |
GB201300533D0 (en) | Methods of monitoring conditions by sequence analysis | |
WO2009025852A3 (en) | Methods of using mirna for detection of in vivo cell death | |
EP2596132A4 (en) | METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS | |
WO2006073682A3 (en) | Diagnostic test | |
MXNL05000103A (es) | Panal diagnostico. | |
EP4273548A3 (en) | Serologic assay for silent brain ischemia | |
EP1981401A4 (en) | MEASURING CARDIAC FLOW AND BLOOD VOLUME BY NON-INVASIVE DETERMINATION OF INDICATOR DILUTION | |
Zhang et al. | Seasonal influenza-associated intensive care unit admission and death in tropical Singapore, 2011-2015 | |
WO2012074882A3 (en) | Phagocytic activity as a marker of synucleinopathic disease | |
DE502008002764D1 (de) | Diagnostisches einmalteil | |
DE602006015221D1 (de) | Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression | |
JP2007330263A5 (pt) | ||
EP2023803A4 (en) | MEASUREMENT OF HEART TIME VOLUME AND BLOOD VOLUME BY NON-INVASIVE DETECTION OF INDICATOR THINNING FOR HEMODIALYSIS | |
CN203153737U (zh) | 肺功能检测细菌过滤器 | |
RU2010122123A (ru) | Способ прогнозирования психоэмоционального состояния пациентов на стоматологическом приеме и возможности коррекции | |
RU2007132384A (ru) | Способ прогнозирования и диагностики гиперфибринолиза | |
BR112022019112A2 (pt) | Métodos e tratamento envolvendo excesso de light livre | |
Kuo et al. | Assessment of Procedures for Arriving Passengers with Fever or Respiratory Tract Symptoms at International Airports | |
Merkt et al. | Horses diagnosed clinically and by laboratory methods for Bornavirus infection and treated with amantadine:“Patients” of the Tierärztliche Klinik für Pferde in Meerbusch. | |
BRPI0903797A8 (pt) | Método para diagnóstico e monitoramento de alfa-sinucleinopatias pela determinação de níveis de mirnas em amostras biológicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |